Bicalutamide
(asked on 10th May 2022) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the therapeutic benefits of bicalutamide in halting the growth of prostate cancer; and if he will make a statement.
Answered by
Maria Caulfield
Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
We have made no specific assessment. However, bicalutamide (casodex) has been licensed in the United Kingdom for the treatment of advanced prostate cancer since 2000. The National Institute for Health and Care Excellence has made recommendations on use of bicalutamide in its guideline on the diagnosis and management of prostate cancer, which is available at the following link:
https://www.nice.org.uk/guidance/ng131/chapter/Recommendations